Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...
In 2021, alcohol-related liver cirrhosis accounted for about a quarter of the 46·4 million disability-adjusted life-years (DALYs) lost from liver disease globally, making alcohol a leading cause of ...
SEQUANA MEDICAL ANNOUNCES UPDATE ON SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium – 2 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a ...